Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus BALNEOL HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus BALNEOL HC.
ARAZLO vs BALNEOL-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply a thin layer to affected skin areas twice daily. For adult use, 1% hydrocortisone (as BALNEOL-HC) topical application.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Hydrocortisone: terminal half-life ~1.5–2.5 hours. With BALNEOL-HC (emollient + hydrocortisone 0.5%), systemic absorption after topical use is minimal (~2–5%), but prolonged application to damaged skin may increase systemic exposure, slightly prolonging half-life.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal excretion of metabolites; <10% unchanged. Biliary/fecal elimination is negligible. In children undergoing whole-body application, percutaneous absorption can lead to systemic excretion of hydrocortisone metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid